Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura Treats First Patient in
HARNESS-1 EGFRm Lung Cancer Trial
§ First patient has been treated in the HARNESS-1 Phase 1 RC220 lung cancer trial with no adverse
events observed
§ RC220 is being assessed alongside osimertinib in EGFR-mutant NSCLC, where osimertinib
resistance is a major clinical challenge
§ Additional clinical trial sites are expected to open in the coming months, supporting increased pa-
tient recruitment and study progress
25 June 2026
Racura Oncology Limited (“Racura”) is pleased to announce that the first patient has been treated with
RC220 at 50mg/m2
in the Phase 1 HARNESS-1 clinical trial. The treatment of the first patient marks the
start of patient dosing in this important clinical program. The patient was treated by Principal Investigator
Associate Professor Surein Arulananda and his team at Monash Health (Clayton, Victoria). No adverse
events were observed during or after the RC220 infusion.
HARNESS-1 is evaluating whether RC220 (E,E-bisantrene) can be safely combined with the standard-of-
care tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso®; AstraZeneca) in patients with EGFR-mutant
non-small cell lung cancer (NSCLC). Patients with this form of lung cancer can benefit from targeted TKI
therapy, but resistance to TKI treatments remains a significant clinical challenge.
The study uses single-patient cohorts for the first three dose escalations (50mg/m2
, 100mg/m2
and
150mg/m2
), before progressing to larger cohorts to identify the maximum tolerated dose (MTD) of RC220
in combination with osimertinib. This staged approach is designed to support careful dose escalation while
generating early safety and pharmacokinetic (PK) data. Patients will continue treatment with RC220 and
osimertinib until one year of treatment is completed, disease progression, unacceptable toxicity,
withdrawal of consent, or another protocol-defined discontinuation criterion occurs.
Racura Oncology CEO/MD, Dr Daniel Tillett commented: “Treating the first patient in HARNESS-1 is an
important step in the clinical development of RC220 and reflects the progress being made across Racura’s
oncology pipeline. This trial is focused on a patient group where resistance to current targeted therapies
remains a significant challenge. We are grateful to A/Prof Surein Arulananda and his team at Monash Health
for their work in recruiting and treating the study’s first participant, and we thank the patients and families
supporting this clinical research.”
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
HARNESS-1 Trial Overview
HARNESS-1 is a multi-centre Phase 1a/b clinical study in patients with EGFR-mutant NSCLC receiving
osimertinib. The study includes an observational (screening) stage that uses circulating tumour DNA
(ctDNA), a blood-based marker of cancer activity and growth, to help identify and enrol patients eligible for
RC220 treatment.
The first treatment stage will assess increasing doses of RC220, administered by intravenous infusion on
Day 1 of each 21-day cycle, in combination with standard-of-care maintenance osimertinib. This stage is
designed to assess safety and identify an appropriate dose for further study. Between 12 and 40 patients
are expected to participate in the dose-escalation stage of the trial.
After the recommended dose has been established and reviewed against available safety and PK data, the
study will move into a double-blind, randomised Phase 1b expansion stage. In this dose expansion stage,
40 patients will receive one of two RC220 dose levels in combination with osimertinib. Patients will be
monitored for safety, PK and clinical activity measures, including progression-free survival, overall survival,
changes in ctDNA levels and changes in cancer-specific mutations.
HARNESS-1 Trial Information
The details of the HARNESS-1 trial, including open and recruiting sites, are provided on the Australian and
New Zealand public clinical trial registry: www.anzctr.org.au, with the trial code ACTRN12626000325303.
Enquiries can be directed via email to Racura Oncology at trials@racuraoncology.com.
-ENDS-
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3
About Racura Oncology
Racura Oncology (ASX: RAC) is a clinical-stage biopharmaceutical company developing new approaches
to treat cancer.
Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent designed to silence cancer
growth pathways through G4-DNA and RNA binding, including the cancer growth regulator MYC. (E,E)-
bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety
profile. Recent Racura discoveries have enabled composition of matter IP filings that provide for 20 years
of patent protection over (E,E)-bisantrene.
Racura is advancing RC220, a proprietary formulation of (E,E)-bisantrene, across multiple oncology
indications. Its clinical programs include a Phase 3 program in acute myeloid leukaemia (AML), a Phase
1a/b program in EGFR-mutant NSCLC, and a Phase 1a/b program in combination with doxorubicin for solid
tumour patients.
Racura has collaborated with leading research and clinical organisations including Astex, Emory University,
Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong,
and University of Newcastle. Racura is also exploring partnerships, licence agreements, and other
commercial opportunities to support the development of RC220.
If you have any questions on this announcement, or any past Racura Oncology announcements, please
visit our Interactive Announcements page.
Racura encourages all investors to go paperless by registering their details with the Company’s share
registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO/MD Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover